Media headlines about Axsome Therapeutics (NASDAQ:AXSM) have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Axsome Therapeutics earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.0370915008299 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Several research firms have recently issued reports on AXSM. ValuEngine upgraded shares of Axsome Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Zacks Investment Research upgraded shares of Axsome Therapeutics from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a report on Thursday, December 14th. Finally, Cantor Fitzgerald set a $13.00 price objective on shares of Axsome Therapeutics and gave the company a “buy” rating in a report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Axsome Therapeutics presently has an average rating of “Buy” and an average target price of $16.90.
Axsome Therapeutics (AXSM) traded up $0.10 on Friday, hitting $2.70. 328,114 shares of the stock traded hands, compared to its average volume of 565,443. Axsome Therapeutics has a 12-month low of $2.45 and a 12-month high of $6.45. The company has a current ratio of 3.86, a quick ratio of 3.86 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $71.36 and a P/E ratio of -1.99.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.